Turning Point Therapeutics's net tangible assets is $790M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2022), TPTX shows a net tangible assets of $790M. That compares with $1.1B in the prior-year period — down 25.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TPTX's net tangible assets is now $790M (was $1.1B) — a 25.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Turning Point Therapeutics is outperforming or lagging.
Tracking TPTX's net tangible assets over time shows whether Turning Point Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $790M That compares with $1.1B in the prior-year period — down 25.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Turning Point Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $790M) with ownership activity and broader fundamentals.
Turning Point Therapeutics's net tangible assets is $790M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.